InsiderTrades.com logo
The only candlestick pattern worth a darn
From WealthPress   |   Ad
It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…
Follow this link here and enter your email address to sign up…
John Renger net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

John Renger Biography and Net Worth

Insider of Cerevel Therapeutics
John Renger, Ph.D., has served as our Chief Scientific Officer since May 2019.

Dr. Renger joined Cerevel Therapeutics from Imbrium Therapeutics L.P., where he served as vice president of research and development and regulatory affairs, leading the company’s overall scientific direction and clinical development strategy. Previously, Dr. Renger held roles of increasing responsibility at Merck & Co. over a 15-year tenure, most recently serving as associate vice president.

Dr. Renger was a postdoctoral fellow at the Massachusetts Institute of Technology Center for Learning and Memory and previously worked at the RIKEN Brain Science Institute in Japan. Dr. Renger earned his Ph.D. in biological sciences with a focus on neurogenetics at the University of Iowa where he also completed his B.S. in biology.

What is John Renger's net worth?

The estimated net worth of John Renger is at least $286,395.20 as of February 7th, 2024. Dr. Renger owns 6,370 shares of Cerevel Therapeutics stock worth more than $286,395 as of November 16th. This net worth approximation does not reflect any other investments that Dr. Renger may own. Additionally, Dr. Renger receives a salary of $779,750.00 as Insider at Cerevel Therapeutics. Learn More about John Renger's net worth.

How old is John Renger?

Dr. Renger is currently 55 years old. There are 7 older executives and no younger executives at Cerevel Therapeutics. The oldest executive at Cerevel Therapeutics is Mr. Kenneth A. DiPietro, Chief Human Resources Officer, who is 65 years old. Learn More on John Renger's age.

What is John Renger's salary?

As the Insider of Cerevel Therapeutics Holdings, Inc., Dr. Renger earns $779,750.00 per year. There are 2 executives that earn more than Dr. Renger. The highest earning executive at Cerevel Therapeutics is Dr. N. Anthony Coles Jr., M.P.H., Executive Chairman, who commands a salary of $1,140,000.00 per year. Learn More on John Renger's salary.

How do I contact John Renger?

The corporate mailing address for Dr. Renger and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on John Renger's contact information.

Has John Renger been buying or selling shares of Cerevel Therapeutics?

John Renger has not been actively trading shares of Cerevel Therapeutics within the last three months. Most recently, John Renger sold 2,161 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $41.54, for a transaction totalling $89,767.94. Following the completion of the sale, the insider now directly owns 6,370 shares of the company's stock, valued at $264,609.80. Learn More on John Renger's trading history.

Who are Cerevel Therapeutics' active insiders?

Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.

Are insiders buying or selling shares of Cerevel Therapeutics?

In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 236,864 shares worth more than $9,768,056.92. The most recent insider tranaction occured on July, 1st when Director N Anthony Coles sold 25,000 shares worth more than $1,029,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.

Information on this page was last updated on 7/1/2024.

John Renger Insider Trading History at Cerevel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2024Sell2,161$41.54$89,767.946,370View SEC Filing Icon  
10/4/2022Sell25,000$30.00$750,000.002,704View SEC Filing Icon  
8/10/2022Sell55,000$40.50$2,227,500.002,704View SEC Filing Icon  
7/20/2022Sell25,000$30.00$750,000.002,704View SEC Filing Icon  
7/5/2022Sell25,000$30.00$750,000.002,704View SEC Filing Icon  
4/13/2022Sell45,000$34.65$1,559,250.001,980View SEC Filing Icon  
3/29/2022Sell10,000$35.00$350,000.00View SEC Filing Icon  
3/18/2022Sell20,000$32.50$650,000.00View SEC Filing Icon  
3/16/2022Sell25,000$30.00$750,000.00View SEC Filing Icon  
2/9/2022Sell25,000$30.00$750,000.00View SEC Filing Icon  
12/27/2021Sell4,127$35.00$144,445.00View SEC Filing Icon  
12/23/2021Sell5,873$35.00$205,555.00View SEC Filing Icon  
12/21/2021Sell7,300$32.50$237,250.00View SEC Filing Icon  
12/17/2021Sell7,122$32.50$231,465.00View SEC Filing Icon  
12/15/2021Sell25,000$30.02$750,500.00View SEC Filing Icon  
11/10/2021Sell55,000$39.86$2,192,300.00View SEC Filing Icon  
See Full Table

John Renger Buying and Selling Activity at Cerevel Therapeutics

This chart shows John Renger's buying and selling at Cerevel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerevel Therapeutics Company Overview

Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $44.96
Low: $44.96
High: $44.96

50 Day Range

MA: $43.67
Low: $40.30
High: $44.96

2 Week Range

Now: $44.96
Low: $19.59
High: $44.99

Volume

N/A

Average Volume

1,709,788 shs

Market Capitalization

$8.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4
The only candlestick pattern worth a darn
From WealthPress   |   Ad
It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…
Follow this link here and enter your email address to sign up…